1 2014 Earnings summary
2 Earnings by Subsidiary
3 4Q 2014Earnings summary
4 Financial summary

[^0]AMOREPACIFIC Group has adopted the K-IFRS since 2011.

IR ${ }^{2014} \mid 2014$ Earnings summary

Sales up 21\% to KRW 4,711.9bn, OP up 40\% to KRW 659.1bn

Sales \& OP by Division

|  | 2013 | \% of sales | 2014 | \% of sales | YoY(\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | $3,895.4$ | 100.0 | $4,711.9$ | 100.0 | 21.0 |
| Cosmetics1) | $3,624.8$ | 93.1 | $4,467.8$ | 94.8 | 23.3 |
| Non-cosmetics2) | 270.6 | 6.9 | 244.2 | 5.2 | -9.8 |
| Operating Profit | 469.8 | OPM | 2014 | OPM | YoY(\%) |
| Cosmetics | 460.3 | 12.1 | 659.1 | 14.0 | 40.3 |
| Non-cosmetics | 9.5 | 12.7 | 663.8 | 14.9 | 44.2 |
| Net Profit | 355.0 | 3.5 | $(4.7)$ | $(1.9)$ | Turned to red |

1) Cosmetics: AMOREPACIFIC, Etude, Innisfree, Amos Professional, Adjustment
2) Non-cosmetics: APG, Pacific Pharma., Pacific Glas, Pacific Package, Jangwon Industry

IR ${ }^{2044} \mid$ Earnings by Subsidiary $(1 / 3)$

Cosmetics
Sales


Non-cosmetics

Sales


* Pacific Pharma.: Decreased sales due to the transfer of
(YoY)
pharmaceutical business


Earnings by Subsidiary(2/3)

## AMOREPACIFIC: Sales $+\mathbf{2 5 \%}$, OP +52\%

Domestic cosmetics
-(Luxury) Continued strong travel retail growth backed by increased sales to foreign travelers, Secured foothold for healthy growth through door-to-door innovation

- (Premium) Solid Aritaum growth delivered by strengthened competitiveness of products, channel and services, Robust digital growth on the back of enhanced brand power and diversified product category


## Mass \& Sulloc

- (Mass) Expanded premium business backed by strong growth from cosmetic category but sales slightly decreased due to the change of market environment and consumption slowdown
- (Sulloc) Increased contribution of premium business behind by improved brand awareness of OSULLOC

Overseas business

- (Growth markets) Achieved strong profitable growth resulted from reinforced brand recognition and strengthened distribution portfolio through channel diversification
- (Developed markets) Increased sales across all channels resulted in strong sales growth and turned to black in US / Efficient cost management resulted in decreased losses in France but sales decreased due to market slowdown / Decreased sales in Japan due to the realignment of brand and channel portfolio


## Innisfree: Sales +37\%, OP +54\%

- Solid profitable growth across all channels delivered by increased sales of major products(Green tea, Jeju volcanic line) and launch of new products(Jeju Orchid, Creamy tint lip mousse, Smart Foundation, etc.)
- Increased export sales on the back of accelerated overseas business, strong growth of travel retail behind by increased foreign travelers
- Improved profitability led by increased sales per door and reduced discount policy


## Etude: Sales -9\%, OP -79\%

- Overall sales decreased due to reduced discount policy and cuts in transaction with overseas agents
- Decreased OP due to weakened sales and increased investment in marketing activities to reinforce brand power

|  | 2013 | 2014 |
| :---: | :---: | :---: |
|  | AMOREPACIFIC _ Consolidated |  |
| Sales | 3,100.4 | 3,874.0 |
| GP | 2,188.6 | 2,845.8 |
| SG\&A expenses | 1,818.8 | 2,282.1 |
| OP | 369.8 | 563.8 |
|  | Innisfree |  |
| Sales | 332.8 | 456.7 |
| GP | 232.0 | 325.7 |
| SG\&A expenses | 182.2 | 249.2 |
| OP | 49.8 | 76.5 |
|  | Etude |  |
| Sales | 337.2 | 306.5 |
| GP | 189.3 | 173.2 |
| SG\&A expenses | 163.2 | 167.6 |
| OP | 26.1 | 5.6 |

- Continued efforts to strengthen brand equity including reestablishment of brand story and renovation of store design


## IR ${ }^{2044} \mid$ Earnings by Subsidiary(3/3)

## Amos Professional: Sales +12\%, OP +1\%

- Strong growth backed by increased sales of major products such as 'Feel the Green Tea' line and curling essence in hair tonic and colorants categories
- Increased commissions caused by strong growth from travel retail

Pacific Pharma.: Sales -37\%, OP -186\% (Like-for-like sales +6\%)

- Decreased sales and OP due to the transfer of pharmaceutical business
- Medical beauty division backed by increased sales of ATObarrier and launch of new product, Cleviel, delivered double digit growth with reinforced market positioning(+15\%)
- Decreased profit due to increased investment in marketing to strengthen the capabilities as a Medical Beauty company


## Pacific Glas: Sales $+5 \%$, Losses continued

- Strong growth delivered by solid performance of cosmetics affiliates
- Increased expenses due to the renovation of product facilities

|  | 2013 | 2014 |
| :---: | :---: | :---: |
|  | Amos Professional |  |
| Sales | 49.0 | 54.6 |
| GP | 24.6 | 29.3 |
| SG\&A expenses | 13.1 | 17.7 |
| OP | 11.5 | 11.6 |
|  | Pacific Pharma. |  |
| Sales | 125.4 | 79.1 |
| GP | 49.3 | 19.9 |
| SG\&A expenses | 45.0 | 23.5 |
| OP | 4.3 | -3.6 |
|  | Pacific Glas |  |
| Sales | 61.2 | 64.1 |
| GP | 3.9 | 2.6 |
| SG\&A expenses | 5.2 | 5.3 |
| OP | -1.3 | -2.7 |

IR $_{2004}^{20} \mid 402014$ Earnings summary

Sales up $32 \%$ to KRW 1,186.4bn, OP up 50\% to KRW 99.Obn

Sales \& OP by Division

|  | 40.2013 | \% of sales | 40.2014 | \% of sales | YoY(\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | 899.8 | 100.0 | $1,186.4$ | 100.0 | 31.8 |
| Cosmetics1) | 833.6 | 92.6 | $1,125.3$ | 94.8 | 35.0 |
| Non-cosmetics2) | 66.3 | 7.4 | 61.1 | 5.2 | -7.8 |
| Operating Profit | 60.2013 | OPM | 40.2014 | OPM | YoY(\%) |
| Cosmetics | 63.4 | 7.3 | 99.0 | 8.3 | 50.1 |
| Non-cosmetics | 2.5 | 7.6 | 101.4 | 9.0 | 59.8 |
| Net Profit | 50.1 | 3.8 | $(2.4)$ | $1.9)$ | Turned to red |

1) Cosmetics: AMOREPACIFIC, Etude, Innisfree, Amos Professional, Adjustment
2) Non-cosmetics: APG, Pacific Pharma., Pacific Glas, Pacific Package, Jangwon Industry

## Income statement

KRW bn

|  | 2013 |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | $3,895.4$ | $100.0 \%$ | $4,711.9$ | $100.0 \%$ |
| Gross profit | $2,695.9$ | $69.2 \%$ | $3,403.8$ | $72.2 \%$ |
| SG\&A expenses | $2,226.2$ | $57.1 \%$ | $2,744.7$ | $58.2 \%$ |
| Operating profit | 469.8 | $12.1 \%$ | 659.1 | $14.0 \%$ |
| Non-operating <br> profit/expenses | 12.1 |  | 22.7 |  |
| Profit before tax <br> Consolidated net <br> income | 481.9 | $12.4 \%$ | 681.8 | $14.5 \%$ |
| 355.0 | $9.1 \%$ | 497.4 | $10.6 \%$ |  |

Statements of Financial Position
KRW bn

| Assets | 2013.12 | 2014.12 |
| :---: | :---: | :---: | :---: |
| Current assets | $4,921.9$ | $5,499.7$ |
| Non-current assets | $1,552.3$ | $2,098.1$ |
| Liabilities | $3,369.6$ | $3,401.7$ |
| Current liabilities | $1,012.9$ | $1,175.9$ |
| Non-current liabilities | 644.3 | 773.1 |
| Shareholder's Equity | 368.6 | 402.8 |
| Capital stock | $3,908.9$ | $4,323.8$ |
| Additional paid-in capital | 673.0 | 44.5 |
| Capital surplus | 22.6 | 673.0 |
| Other components of equity | $(140.8)$ |  |
| Accumulated other | $(7.3)$ | 22.6 |
| comprehensive income | $1,533.7$ |  |
| Retained earnings | $1,783.3$ |  |
| Non-controlling interest |  | $(4.3)$ |


[^0]:    As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

